

10/7/2020

PloSOne

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**A protease protection assay for the detection of internalized alpha-synuclein pre-formed fibrils**

Timothy S. Jarvela, Kriti Chaplot and Iris Lindberg\*

Department of Anatomy and Neurobiology

University of Maryland-Baltimore, Baltimore MD 21201

Keywords: synuclein, Parkinson’s disease, TEV, endocytosis, neurodegeneration

*\*To whom correspondence should be directed:*

Iris Lindberg, Ph.D.

Department of Anatomy and Neurobiology

20 Penn St., HSF2, S218

University of Maryland-Baltimore

Baltimore, MD 21201

Email: [ilindberg@som.umaryland.edu](mailto:ilindberg@som.umaryland.edu)

Phone: 410 706 4778

## 26 **ABSTRACT**

27 Alpha-synuclein pre-formed fibrils (PFFs) represent a promising model system for the study of cellular  
28 processes underlying cell-to-cell transmission of  $\alpha$ -synuclein proteopathic aggregates. However, the  
29 ability to differentiate the fate of internalized PFFs from those which remain in the extracellular  
30 environment remains limited due to the propensity for PFFs to adhere to the cell surface. Removal of PFFs  
31 requires repeated washing and/or specific quenching of extracellular fluorescent PFF signals. In this paper  
32 we present a new method for analyzing the fate of internalized  $\alpha$ -synuclein. We inserted a tobacco etch  
33 virus (TEV) protease cleavage site between  $\alpha$ -synuclein and green fluorescent protein. As the TEV  
34 protease is highly specific, non-toxic, and active under physiological conditions, we are able to use  
35 protection from TEV cleavage to distinguish internalized PFFs from those which remain attached to the  
36 cell surface. Using this experimental paradigm, downstream intracellular events can be analyzed via live  
37 or fixed cell microscopy as well as by Western blotting. We suggest that this method will be useful for  
38 understanding the fate of PFFs after endocytosis under various experimental manipulations.

## 39 **INTRODUCTION**

40 Cell-to-cell transmission of proteopathic aggregates is increasingly understood to represent the  
41 underlying cause of the stereotypical spread of  $\alpha$ -synuclein pathology observed in Parkinson's disease  
42 [1]. A variety of model systems have been developed to replicate this process *in vivo* [2-7] as well as in  
43 primary and immortalized cell culture [8-10]. Taken together, these experimental models have identified  
44 specific cellular components responsible for the internalization and transmission of  $\alpha$ -synuclein.

45 Pre-formed fibrils (PFFs) represent a molecular form of  $\alpha$ -synuclein thought to represent a good proxy for  
46 the cytotoxic species produced *in vivo* (reviewed in [10]). However, it has been difficult to develop  
47 experimental methods that permit the biochemical discrimination of intracellular PFFs from those  
48 remaining extracellularly, for example PFFs coating the cell surface. This problem is especially difficult to  
49 overcome given the known stickiness of synuclein aggregates. While trypan blue treatment of GFP-tagged  
50 synuclein has been used to quench the GFP signal from surface-attached PFFs [10], this method cannot  
51 be used in concert with immunocytochemical or biochemical analyses, or with prolonged chase periods  
52 following the quench. Because of the limitations of the current cell biology toolkit, our knowledge of the  
53 key processes and molecular players involved in the fate of pathological extracellular  $\alpha$ -synuclein seeds  
54 following binding and internalization remains limited.

55 We here present a method for the specific detection of internalized  $\alpha$ -synuclein PFFs. The assay provides  
56 an intact vs cleaved protein readout in response to incubation with or without TEV protease. With this  
57 method, intracellular  $\alpha$ -synuclein PFFs are protected against cleavage due to the impermeability of the  
58 plasma membrane. The ability of membranes to block protease cleavage of target proteins has frequently  
59 been used to determine the subcellular localization and topology of transmembrane domain-containing  
60 proteins ([11]; reviewed in [12]). Here, we employ GFP-tagged  $\alpha$ -synuclein PFFs containing an engineered  
61 TEV-P cleavage site to efficiently discriminate between intracellular and extracellular PFFs.

## 62 **METHODS**

### 63 **Plasmids**

64 pET21a-  $\alpha$ -synuclein, encoding human  $\alpha$ -synuclein, was a gift of the Michael J. Fox Foundation (Addgene  
65 plasmid #51486). The pRK172-mouse  $\alpha$ -synuclein-GFP plasmid was a kind gift of Dr. Virginia Lee

66 (University of Pennsylvania) [10]. The tobacco etch virus protease (TEV) site (ENLYFQ<sup>~</sup>G) was inserted  
67 following the 6x His tag, in frame with the start of the GFP sequence. A forward primer (5'-TAT TTT CAG  
68 GGC ATG GTG AGC AAG GGC GAG-3') and reverse primer (5'- AAG ATT CTC GAG ATG GTG ATG GTG ATG  
69 G-3') were combined using the Q5 site-directed mutagenesis protocol (New England Biolabs, Ipswich,  
70 MA). The resulting plasmid, pRK172- $\alpha$ -syn-TEV-GFP, was sequenced and transformed into competent  
71 BL21(DE3) cells (Thermo Fisher Scientific, Waltham, MA, Cat# EC0114) for protein production.

## 72 **Protein Expression and Purification**

73 Protein production was performed using a protocol adapted from [13]. A 5 ml starter culture of  
74 transformed bacteria was incubated in LB broth (Sigma, St. Louis, MO) with ampicillin (50 ug/ml) at 37°C  
75 overnight. One liter of autoinduction media (10 g tryptone, 5 g yeast extract, 2 ml 1 M MgSO<sub>4</sub>, H<sub>2</sub>O to 930  
76 ml) was autoclaved and completed by adding 50 ml of filter-sterilized 20x NPS (20x NPS: 0.5 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>;  
77 1 M KH<sub>2</sub>PO<sub>4</sub>, 1 M Na<sub>2</sub>HPO<sub>4</sub>) and 20 ml of filter-sterilized 50x 5052 (50x 5052: 50 g glycerol, 5 g glucose, 20  
78 g lactose; H<sub>2</sub>O to 200 ml) prior to inoculating autoinduction media with starter culture. The culture was  
79 then grown in a shaking incubator at 30°C for 24 h. Cells were harvested by centrifugation at 4000 x g at  
80 4°C for 20 min and the pellet frozen at -20°C for later use.

81 Pellets were thawed at room temperature and resuspended in a 10% volume of osmotic shock buffer (100  
82 ml per 1000 ml culture; 30 mM Tris pH 7.2, 2 mM EDTA, 40% sucrose). The suspension was centrifuged at  
83 9000 x g at 20°C for 20 min. The supernatant was discarded (a small amount of  $\alpha$ -synuclein-GFP remains  
84 in the supernatant at this point and can be recovered by dialysis into buffer A) and the pellet was  
85 resuspended in 40 ml of ice-cold H<sub>2</sub>O. A saturated MgCl<sub>2</sub> solution was added to the resuspension at a  
86 1:1000 dilution (40  $\mu$ l). The mixed suspension was incubated on ice for 3 min, and then centrifuged at 4°C  
87 for 30 min at 9000 x g. The visibly green supernatant was collected; at this point, it was highly fluorescent  
88 under UV light. The supernatant was loaded onto a 1 ml HiTRAP DEAE column (GE Healthcare, Boston,  
89 MA) for ion exchange chromatography using an GE Akta Purifier (buffer A: 20 mM Tris-HCl, pH 7.4 (at 4°C),  
90 buffer B: 20 mM Tris, 1 M NaCl, pH 7.4 (at 4°C)). The purification protocol was as follows: 1 column volume  
91 (CV) buffer A; 2 CV 5% buffer B; 2 CV ramp to 10% buffer B; 2 CV 10% buffer B; 18 CV ramp to 80% buffer  
92 B, 2.5 ml fractions; 2 CV ramp to 95% buffer B; and 3 CV at 95% buffer B to finish washing. Eluted fractions  
93 can be identified using a hand-held UV-A light (wavelength 315-400 nm); fractions containing GFP appear  
94 yellow under normal light and fluoresce green under ultraviolet light. Alternatively, the elution peak can  
95 be determined by measuring absorbance at 488 nm. An aliquot of each fraction was analyzed by SDS  
96 polyacrylamide electrophoresis (SDS-PAGE; see below) followed by Coomassie staining, and fractions with  
97 strong  $\alpha$ -syn-TEV-GFP bands were combined and further purified by His-tag affinity chromatography.  
98 Human untagged  $\alpha$ -synuclein used for *in vitro* fibrillation assays was prepared in a similar manner.

## 99 **PFF Generation**

100 Lyophilized  $\alpha$ -syn-TEV-GFP protein was resuspended in a small volume of Dulbecco's PBS (dPBS), filtered  
101 through a 0.45  $\mu$ m filter, and diluted to 7.5 mg in a final volume of 1 ml in dPBS diluted 1/3 with water, as  
102 described in [10]. The suspension was then shaken for 7 days at 37 °C in a 1.5 ml microcentrifuge tube  
103 [10]. After 2 days the mixture became turbid. On day 7, the mixture was vortexed vigorously to create a  
104 homogeneous suspension that was then aliquoted into 50  $\mu$ l single-use aliquots and frozen at -80. For  
105 experiments, one aliquot was rapidly thawed and kept at room temperature. Ten  $\mu$ l of fibril suspension  
106 were added to 490  $\mu$ l dPBS and sonicated using a Branson sonicator with a 0.125 inch microtip, 10%  
107 power, 50% duty cycle, for 90 sec at room temperature. PFFs were not placed on ice, as that has been  
108 shown to lead to dissociation of fibrils [14].

## 109 **Cell Culture**

110 Neuro2A cells (ATCC #CCL-131; Gaithersburg, MD) were grown at 37° C at 5% CO<sub>2</sub> in OptiMEM/F12  
111 (50/50; ThermoFisher Scientific) with 5% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA).

## 112 **Protease Protection Assay**

113 TEV protease (TEV-P) was purchased from NEB (Cat#P8112S). PFFs were prepared as above and premixed  
114 1:10 (for a final concentration of 15 µg/ml) into OptiMEM (ThermoFisher Scientific). The PFF/OptiMEM  
115 mixture was then added to cells in various volumes of OptiMEM (10 µl for microwell inserts, 100 µl for  
116 48-well plates) and incubated for approximately 1 h. TEV-P (10,000 units/ml stock) was diluted 1:10 in  
117 OptiMEM; this TEV-P/OptiMEM mixture was then diluted a further ten-fold into each well to a final  
118 concentration of 100 units/ml (1 µl for microwell inserts, 10 µl for 48-well plates). Controls were treated  
119 similarly, but using enzyme storage buffer (50 mM Tris-HCl, 250 mM NaCl, 1 mM EDTA, 50% glycerol) in  
120 place of TEV-P. The cells/PFFs were incubated in the presence of TEV-P or buffer for either 30 min (imaging  
121 experiments) or 60 min (Western blot experiments).

## 122 **Lysotracker Experiment**

123 Cells were grown and treated with PFFs as in the protease protection assay with the following additions.  
124 During the TEV-P treatment incubation, LysoTracker® Red DND-99 (Molecular Probes, Life  
125 Technologies) was added at 50 nM final concentration. At the end of TEV-P and Lysotracker incubation,  
126 cells were rinsed 1x in prewarmed media without TEV-P or Lysotracker, fresh media were added to the  
127 cells, and images were acquired as described below.

128

## 129 **Primary Neuron Experiment**

130 Primary hippocampal neurons were prepared as described [15]. Twenty thousand cells were plated on  
131 poly-L-lysine coated coverslips placed in a 24-well plate and allowed to differentiate in NeuroBasal  
132 medium containing 1X Glutamax, 20 µg/ml gentamycin and the B27 supplement (Sigma) for 7 days (all  
133 reagents were obtained from Sigma). The cells were then treated with 5 µg/ml GFP-TEV- $\alpha$ -syn PFFs for 1  
134 h, followed by treatment with TEV-P for 30 min, with rinsing with culture medium after each step. After 4  
135 more days of incubation in culture, cells were fixed in 4% paraformaldehyde for 15 min. Samples were  
136 stained with chicken anti-GFP antibody (AVES, Cat#GFP-1010, 1:1000) overnight at 4 C, followed by anti-  
137 chicken IgY Alexa fluor 647 (Invitrogen, Cat#A32933, 1:1000) and Hoescht stain for 1 h at room  
138 temperature. Samples were imaged using a Leica SP8 40X oil immersion objective.

## 139 **Confocal Microscopy**

140 Neuro2A cells were grown in 4-well micro-inserts (Ibidi, Planegg, Germany; #80409) attached to  $\mu$ -Dish  
141 35-mM gridded polymer cover-slipped dishes (Ibidi, #81166) to allow concurrent imaging of multiple  
142 conditions as well as to minimize the volume of reagents required. Cells were seeded at approximately  
143  $2 \times 10^4$  cells per well, in 10 µl of media, one day prior to PFF treatment. Excess media was added around  
144 the micro-insert as an evaporation barrier, as per the manufacturer's protocol. PFFs and TEV-P were  
145 added as described above. Post-TEV-P treatment images of GFP fluorescence were acquired (EX:488 nm,  
146 EM: 500-550 nm) and 10 µl of 2 mM trypan blue in dPBS was then added to each microwell to quench  
147 extracellular fluorescence. After 1 min a post-quench image was acquired both for GFP fluorescence and  
148 for trypan blue fluorescence (excitation: 561 nm; emission: 570-640 nm). For Lysotracker experiments,  
149 Lysotracker red images were acquired with a 561 nm excitation laser and a 570-640 nm emission filter.  
150 Live cell confocal microscopy was performed on a Nikon W1 spinning disk confocal system (Nikon Ti2  
151 inverted microscope; Hamamatsu sCMOS camera), at the Confocal Microscopy Core Facility, University of

152 Maryland-Baltimore. Acquisition was controlled using Nikon Elements software. Cells were incubated at  
153 37°C and under 5% CO<sub>2</sub> in Opti-MEM during imaging. Image analysis was performed with ImageJ using the  
154 “Analyze Particles” plugin to measure total fluorescence signal for a 3D image stack.

### 155 **Viability Analysis**

156 Neuro2A cells were plated at 4000 cells/ well in complete medium in a 96-well plate. Twenty-four h later,  
157 the culture medium was removed and replaced with 50 µl of OptiMEM. Fifty µl of OptiMEM containing  
158 either TEV-P, Triton-X, or TEV-P buffer (final concentrations 100 U/ml, 1%, and 2% respectively) were then  
159 added to the appropriate wells in quadruplicate, and the plate incubated at 37 C for 30 min. Buffer-treated  
160 and untreated cells were used as controls. The cells were rinsed once with OptiMEM, the medium  
161 replaced with complete Neuro2A medium, and the cells allowed to recover in the incubator for 24 h. The  
162 culture medium was then removed and replaced with 50 µl of fresh Neuro2A medium. Fifty µl of Neuro2A  
163 medium containing 10 µl of WST-1 reagent (Sigma) were then added to each well and the plate incubated  
164 at 37 C for 2 h. The absorbance of 100 µl of the medium was then measured in a 96-well plate using a  
165 BenchmarkPlus microplate spectrophotometer (Biorad). The absorbance at 690 nm, and the absorbance  
166 of the medium-only blank, were subtracted from the absorbance at 450 nm. The percent survival was  
167 computed by normalizing the absorbance values for each well with the average values from untreated  
168 wells. One-way ANOVA and Tukey’s multiple comparisons tests were performed to determine statistical  
169 significance.

### 170 **SDS-PAGE and Western Blotting**

171 Neuro2A cells were seeded at approximately 1x10<sup>5</sup> cells per well in a 48-well tissue culture plate (Corning).  
172 After 24 h, media were replaced with prepared PFF media (as above, 100 µl per well) and returned to  
173 incubate for 1 h. TEV-P treatment was performed as described above, and cells were incubated for 1 h.  
174 Cells were then quickly denatured by adding 100 µl of 2X sample buffer (100 mM Tris-HCl, 8% SDS, 4% β-  
175 mercaptoethanol, 24% glycerol, 0.02% bromophenol blue, pH 6.8) to the wells. Samples were then heated  
176 at 95°C for 10 min prior to SDS-PAGE electrophoresis. Electrophoresis using Mini-PROTEAN AnyKD precast  
177 gels (BioRad, Richmond, CA) was performed using 15 µl of the lysis solution. The proteins were transferred  
178 to nitrocellulose using a Trans-Blot Turbo Transfer System (BioRad), using the mixed MW protocol (7 min,  
179 1.3 amps). Membranes were blocked in 5% blotting grade non-fat dry milk blocker (BioRad) in Tris-  
180 buffered saline (TBS) containing 0.1% Tween 20 for 30 min and then incubated with mouse anti-α-  
181 synuclein antibody (BD Biosciences, San Jose, CA, cat. #610787) (1:2000 dilution from stock, in blocking  
182 buffer) and rocked overnight at 4°C. Blots were washed 3x for 5 min each in TBS without Tween and  
183 incubated with goat anti-mouse IgG coupled to horseradish peroxidase (BioRad, #170656) at a 1:3000  
184 dilution in blocking buffer for 1 h. Blots were washed again 3x in TBS, and incubated in Clarity ECL (BioRad)  
185 prior to imaging using a BioRad Gel Doc Imager and quantification using Image Lab 6.0 software (BioRad).

### 186 **Electron Microscopy**

187 EM preparation was performed as described in [16]. Copper grids were floated on a droplet of water for  
188 1 min and excess water was wicked away; this wash was repeated once. The grid was then floated on a  
189 suspension containing α-synuclein monomers, fibrils, or sonicated PFFs (each at 150 µg/ml in dPBS) for 1  
190 min. Excess liquid was wicked away and the grid was floated twice in 2% uranyl acetate for one min each.  
191 Excess uranyl acetate was wicked away and grids were allowed to dry. Grids were examined in a Tecnai  
192 T12 transmission electron microscope (ThermoFisher Scientific; formerly FEI Co.; Hillsboro, OR) operated  
193 at 80 kEV. Digital images were acquired using a bottom-mounted CCD camera (Advanced Microscopy

194 Techniques, Corp, Woburn, MA) and AMT600 software. Quantification of fibril length was performed  
195 using ImageJ.

### 196 **Thioflavin T Assay (ThT)**

197 Seeding was performed by adding 5  $\mu$ l of 150 ng/ $\mu$ l sonicated PFFs or monomers in Dulbecco's PBS (dPBS)  
198 to each individual fibrillation reaction. Fibrillations were performed as previously described [17]. Briefly,  
199 in a round bottom 96-well polypropylene dish (Falcon), untagged human  $\alpha$ -synuclein—purified as  
200 previously described [17]—(100  $\mu$ g/well) and 10  $\mu$ M ThT in dPBS (Sigma-Aldrich, St. Louis, MO) were  
201 combined in a final volume of 95  $\mu$ l of dPBS. Seeds (5  $\mu$ l PFF or monomer, in dPBS at 150  $\mu$ g/ml) or an  
202 equivalent volume of PBS (non-seeded control) were added to each well, and then a single 3/32inch  
203 polytetrafluoroethylene bead (McMaster-Carr, Atlanta, GA) was added to each well and the plate sealed  
204 with foil. The plate was then incubated at 37°C while pulse shaking at 1000 RPM on a Microplate Genie  
205 Pulse Digital Mixer (Scientific Industries, Bohemia, NY). The plate fluorescence was measured at the  
206 indicated time points using a SpectraMAX M2 spectrophotometer (Molecular Devices, San Jose, CA), with  
207 an excitation peak at 450 nm and emission peak at 485 nm, and a 475 nm band pass cutoff, with reads  
208 from the bottom. For each time point, three independent reads were taken at 20 sec intervals and values  
209 were averaged together. Each condition had 4 technical replicates, and the experiment was repeated  
210 once.

### 211 **Statistical Analysis**

212 GraphPad Prism 8 (GraphPad Software, La Jolla, USA) was used for statistical analysis and figure  
213 preparation; statistical details are given in figure legends.

## 214 **RESULTS**

215 To generate the construct used in this assay, a seven-residue TEV protease consensus site linker  
216 (ENLYFQG) was inserted after a 6x His-tag C-terminally attached to  $\alpha$ -synuclein and N-terminal to the GFP  
217 tag ( $\alpha$ -syn-TEV-GFP) (**Figure 1A**). The general strategy of the assay involves incubation the generation of  
218  $\alpha$ -syn-TEV-GFP fibrils, which are freshly sonicated to form pre-formed fibrils (PFFs) to permit  
219 internalization. After a short incubation, TEV protease (TEV-P) is added and cells are incubated to permit  
220 cleavage of GFP from alpha-synuclein (**Figure 1B**). As proof-of-concept, purified  $\alpha$ -syn-TEV-GFP PFFs were  
221 incubated with TEV-P *in vitro*. The GFP in these PFFs can be readily cleaved from  $\alpha$ -synuclein, as evidenced  
222 by a single band of high molecular weight (approximately 45 kDa) in untreated wells and smaller bands of  
223 GFP (25 kDa) and  $\alpha$ -synuclein (17 kDa) visible in TEV-P treated lanes (**Figure 1C**).

### 224 **FIGURE 1. Creation and schematic design of a TEV protease-sensitive $\alpha$ -synuclein-GFP fusion** 225 **protein.**

226 **(A)** A schematic diagram of the construct: mouse  $\alpha$ -synuclein, 6x His, TEV protease site, and the GFP  
227 fusion protein. **(B)** Schema of the protease protection assay. Pre-formed fibrils (black) containing GFP  
228 (green) are incubated with cells for 1 h to permit endocytosis into cells. TEV protease (orange) is  
229 added and incubated with cells for 30-60 min for optimal fusion protein cleavage. GFP is cleaved  
230 from PFFs exposed to TEV protease within the media and on cell surfaces. Internalized  $\alpha$ -syn-TEV-  
231 GFP PFFs are protected from TEV cleavage. **(C)** Coomassie-stained gel showing  $\alpha$ -syn-TEV-GFP PFFs  
232 incubated *in vitro* with and without TEV protease for 30 min.

233 While Karpowitz *et al.* have shown that mouse  $\alpha$ -synuclein with a C-terminal GFP-tag can form fibrils, and  
234 that GFP-tagged PFFs are able to spread pathology [10], we verified that the addition of a TEV cleavage

235 site did not reduce the ability of the fusion construct to form fibrils. Using electron microscopy, we first  
236 confirmed the morphology of the  $\alpha$ -syn-TEV-GFP monomers, fibrils, sonicated PFFs, and TEV-incubated  
237 PFFs (**Figure 2A**). These data support the efficacy of the sonication procedure and show that TEV  
238 treatment does not grossly alter PFF morphology. These data are quantified in **Figure 2B**, in which PFF  
239 lengths of TEV-treated and non-TEV-treated PFFs are compared. Others have noted that using PFFs with  
240 an average size of <50 nm is important to improve seeding both *in vivo* and *in vitro* [18]. The new  $\alpha$ -syn-  
241 TEV-GFP PFFs were also capable of seeding fibril formation. The insertion of the TEV protease consensus  
242 site does not interfere with the seeding of untagged human  $\alpha$ -synuclein when assayed using a thioflavin  
243 T fibrillation assay. When 100  $\mu$ g of  $\alpha$ -synuclein monomers were seeded with 750 ng of  $\alpha$ -syn-TEV-GFP  
244 PFFs, the lag phase was reduced compared to wells seeded with monomers or unseeded control wells  
245 (**Figure 2C**). These data confirm that  $\alpha$ -syn-TEV-GFP PFFs made from the construct shown in **Figure 1A** are  
246 fully competent in initiating the fibrillation of monomeric  $\alpha$ -synuclein, a prerequisite for serving as a  
247 model system for  $\alpha$ -synuclein transmission experiments.

#### 248 **FIGURE 2. Characterization of $\alpha$ -syn-TEV-GFP pre-formed fibrils and seeding efficacy.**

249 **(Panel A)** Electron microscopy images of negatively-stained  $\alpha$ -synuclein monomers, intact fibrils,  
250 sonicated fibrils, and sonicated fibrils following TEV treatment. (Scale bar = 200 nm). **(Panel B)**  
251 Histogram of fibril size distribution after sonication with and without TEV treatment (bin size 20 nm;  
252 >200 fibrils counted for each condition). **(Panel C)**  $\alpha$ -syn-TEV-GFP PFFs are competent to seed the  
253 fibrillation of  $\alpha$ -synuclein monomers. Thioflavin T fluorescence, generated following fibril formation,  
254 is shown. (\* $P$ <0.05, two-way ANOVA, Tukey post-test)

255 Following these successful proof-of-concept and quality control assays, we tested the ability of TEV-P to  
256 cleave PFFs attached to cells. Since surface-associated PFFs are exposed to medium TEV-P, while  
257 internalized PFFs are not, treatment of cells with TEV-P can be used to distinguish internalized  $\alpha$ -synuclein  
258 forms. We confirmed internalization of  $\alpha$ -syn-TEV-GFP using the trypan blue quench technique, which  
259 employs this dye to quench extracellular surface-associated GFP [10].  $\alpha$ -syn-TEV-GFP PFFs were added  
260 to cells grown in imaging-polymer bottom dishes at 15  $\mu$ g/ml, and cells incubated for 1 h at 37 C to permit  
261 endocytosis. Cells were then either treated with TEV-P or with buffer for 30 min. Following cleavage by  
262 TEV-P, free GFP is capable of freely diffusing away from the plasma membrane, greatly reducing the  
263 membrane-bound GFP signal. **Figure 3A** depicts confocal images of N2A cells incubated with buffer (*top*  
264 *panel*) or TEV-P (*bottom panels*), either before (*left side*) or after (*right side*) trypan blue quenching. To  
265 control for heterogeneity in GFP signal across differing treatments, the total amount of GFP fluorescence  
266 signal prior to trypan blue addition was normalized to the post-quench GFP signal in each image. Surface  
267 fluorescence in the TEV-P-treated cells is clearly reduced as compared to images obtained prior to trypan  
268 blue quenching, with little additional loss of fluorescence after quenching. Overall, the level of GFP signal  
269 in control-treated cells prior to quenching is approximately 1.9-fold higher than post-trypan blue  
270 quenching (\* $p$ =0.036), whereas in TEV-P treated wells, the signal prior to the quench is not significantly  
271 higher than the post-quench signal (**Figure 3B**). We conclude that TEV-P treatment removes extracellular  
272 GFP signal as effectively as trypan blue quenching.

#### 273 **FIGURE 3. Incubation with TEV protease selectively removes GFP fluorescence from the cell** 274 **surface.**

275 **(Panel A)** Confocal images of Neuro2A cells after incubation with  $\alpha$ -syn-TEV-GFP PFFs (*green*) for 1  
276 h, followed by incubation with (*top*) or without (*bottom*) TEV protease for 30 min. Images are  
277 presented as the average of 3 slices from the middle of a confocal Z-stack (Scale bar = 5  $\mu$ m).

278 **(Panel B)** Quantification of the percent of fluorescence remaining after trypan blue quenching. The  
279 total fluorescence signal in the 3D confocal images was measured both pre- and post-trypan-blue  
280 treatment in four independent experiments; the average for each experiment is shown as a single  
281 data point. Data are presented as a ratio of final post-trypan blue-quenched fluorescence to pre-  
282 trypan blue fluorescence for each individual experiment. ( $*p=0.36$ , *Sidak's multiple comparison test*)

283 **Figure 4** presents quantitative Western blotting data which indicate the utility of the technique in  
284 measuring the amount of internalized PFFs. Neuro2A cells were exposed to PFFs for 60 min to allow  
285 endocytosis; this was then followed by incubation of cells with TEV-P or buffer control for 60 min. In order  
286 to detect total  $\alpha$ -syn-TEV-GFP protein levels, preheated 2x sample buffer was added to the wells without  
287 washing and wells were heated at 95°C for 10 min to efficiently monomerize remaining  $\alpha$ -syn-TEV-GFP  
288 PFFs for SDS-PAGE. These results, showing large quantities of the 45 kDa fusion protein, support the idea  
289 that the majority of the GFP seen in fluorescent images derives from surface-associated  $\alpha$ -syn-TEV-GFP  
290 PFFs (as in **Figure 3**). Exposure of cells to TEV-P removes 95% of this signal (**Figure 4B**), corroborating the  
291 efficacy of extracellular TEV treatment and providing a quantitative measure of PFF internalization.

292 **FIGURE 4. Western blotting provides a quantitative index of internalized intact PFFs.**

293 **(Panel A)** Anti- $\alpha$ -synuclein Western blot, showing the total level of intact  $\alpha$ -syn-TEV-GFP per well  
294 when  $\alpha$ -syn-TEV-GFP PFF-treated cells were incubated with or without TEV protease.

295 **(Panel B)** Quantification of Western blot (triplicate samples, mean  $\pm$  SD).

296 While intracellular expression of TEV-P does not appear to be toxic (reviewed in [12]), we were not able  
297 to find any published data on extracellular use of this enzyme. In order to determine the suitability of this  
298 technique for longer-term experiments, we assessed the potential cytotoxicity of TEV-P treatment using  
299 a WST-1 cytotoxicity assay. We found that cellular viability after 30 min of TEV-P treatment and 24 h of  
300 recovery was comparable to cells treated only with buffer and to untreated cells (**Figure 5**). These data  
301 clearly indicate that exposure to TEV-P is not harmful to cell viability.

302 **FIGURE 5. Exposure of cells to TEV protease is not cytotoxic.**

303 Neuro2A cells were exposed to TEV-P and cell viability measured following an overnight growth  
304 period using the WST-1 cytotoxicity assay. Percent survival is plotted for treatment with TEV-P, 1%  
305 Triton X-100, 1X TEV-P buffer, as well as for untreated cells, by normalizing TEV-treated cell  
306 absorbance values to untreated cell absorbance values. TEV-P treatment does not result in significant  
307 cell death when compared to buffer-treated or untreated cells (one-way ANOVA and Tukey's  
308 multiple comparisons tests).

309 **Figure 6A** presents an example of the use of the TEV-P technique to examine co-localization of internalized  
310 GFP with the lysosomal dye LysoTracker. In the absence of TEV-P treatment, the intense fluorescence  
311 contributed by surface-associated PFFs makes it impossible to detect the signal arising from internalized  
312 PFFs, and thereby, their colocalization with LysoTracker. Following TEV-P treatment, sparse colocalization  
313 of LysoTracker (*red*) with  $\alpha$ -syn-TEV-GFP PFFs (*green*) is seen (**Figure 6A**). In **Figure 6B**, imaging of  
314 differentiated primary hippocampal neurons exposed to  $\alpha$ -syn-TEV-GFP PFFs and then treated with TEV-P  
315 specifically reveals internalized PFFs, as shown by co-localization of GFP fluorescence and GFP  
316 immunoreactivity (assessed 4 days after PFF treatment). We conclude that our method can be readily  
317 coupled with post-treatment cell experimentation.

318 **FIGURE 6. TEV -P-treated cells can be used for fluorescent imaging of internal markers.**



319 **(Panel A) Neuro2A cells.** TEV-P-treated Neuro2A cells exhibit greatly enhanced detection of  
320 internalized  $\alpha$ -syn-TEV-GFP PFFs colocalized with LysoTracker; *white arrows* indicate colocalization.

321 **(Panel B) Differentiated primary hippocampal neurons.** Primary hippocampal cells were fixed and  
322 stained with anti-GFP antiserum (*red*) 4 days post-treatment with 5  $\mu$ g/ml  $\alpha$ -syn-TEV-GFP PFFs  
323 (*green*) and 100 U/ml TEV-P. Images taken at 40X. Scale bar, 20  $\mu$ m. Magnified insert corresponds to  
324 10  $\mu$ m.  
325

## 326 DISCUSSION

327 Mounting evidence suggests that toxic forms of  $\alpha$ -synuclein are propagated throughout the peripheral  
328 and central nervous systems (reviewed in [1]); thus, the uptake and cellular disposition of  $\alpha$ -synuclein is  
329 a topic of increasing research interest. At present, it is difficult to establish the cellular location of added  
330 PFFs, even when tagged with GFP, because PFFs adsorb so efficiently to cell surfaces. While trypan blue  
331 has been successfully used to quench fluorescence arising from surface-associated GFP-PFFs [10], the  
332 trypan blue method does not permit further analysis of PFF-treated cells, for example, to establish the  
333 cellular itinerary of internalized fluorescent PFFs. The data presented here show that LysoTracker can be  
334 used to follow internalized fluorescent GFP-tagged  $\alpha$ -synuclein. Additionally, our data show that  
335 immunohistochemical staining of intracellular GFP (as a proxy for synuclein PFFs), and likely other  
336 intracellular markers, can be performed on TEV-treated cells; this is not possible with the trypan blue  
337 method. Lastly, while our Western blotting experiment included only a single time point, the  
338 disappearance of the internalized intact fusion product over time can potentially be used as a quantitative  
339 measure of intracellular PFF turnover.

340 A key limitation of our method is the fact that TEV treatment removes the fluorescent label but leaves  $\alpha$ -  
341 synuclein still attached to the cell surface; thus,  $\alpha$ -synuclein may still continuously enter the cell while the  
342 internalized fluorescent species is under examination. This is also a limitation of the trypan blue technique:  
343 while outside fluorescence is quenched, GFP-PFFs still remain on the cell surface and are presumably  
344 continuously internalized.

345 The TEV protease method to specifically examine internalized fluorescent GFP can potentially be  
346 expanded to include a variety of applications. One example is the use of internal split TEV systems [19] to  
347 remove fluorescent signal from internalized PFFs under defined cellular conditions. In addition, while we  
348 used a GFP label in this technique as a proof-of-concept, a broad spectrum of protein tags are equally  
349 amenable to similar TEV protease protection assays. Fluorophores that are pH-sensitive,  
350 photoactivatable, or other biological sensors could theoretically be used in place of the GFP tag (although  
351 the efficacy of each tagged synuclein in seeding fibrillation assays would initially need to be tested). In  
352 another possible application, affinity tags could be added to permit selective co-immunoprecipitation of  
353 intracellular PFFs to screen for intracellular interacting partners (reviewed in [12]). The biocompatibility  
354 and specificity of the TEV protease lends itself to a wide variety of potential extensions of this technique.  
355 Interestingly, our use of extracellular TEV appears to be a novel application of the use of this protease.

356 In sum, new tools are required to adequately address the challenges in understanding the cellular events  
357 that underlie intercellular  $\alpha$ -synuclein spreading.  $\alpha$ -Synuclein pathology is based on templated mis-folding  
358 of native monomers; a stable seed drastically increases the rate of  $\alpha$ -synuclein fibrillation/pathology, and  
359 thus the ability to accurately identify the subcellular locations of PFFs during and following the cellular  
360 uptake process is critical. Our technique, which permits further biochemical analysis and continued

361 examination of both fixed and live cells after exposure to fluorescent PFFs, represents a strong  
362 complement to trypan blue quenching.

363 **Acknowledgments:** This work was supported by NIH grant AG 062222 to IL. Sample preparation and  
364 electron microscopy was performed by Dr. Ru-Ching Hsia in the UMB Electron Microscopy Core, while live  
365 cell imaging was performed in the UMB Imaging Core. We thank Minerva Contreras for the initial  
366 preparation of primary hippocampal cells.



## 367 **References**

- 368 1. Uemura N, Uemura MT, Luk KC, Lee VM, Trojanowski JQ. Cell-to-Cell Transmission of Tau and  $\alpha$ -  
369 Synuclein. *Trends Mol Med*. 2020. Epub 2020/05/07. doi: 10.1016/j.molmed.2020.03.012. PubMed PMID:  
370 32371172.
- 371 2. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, et al. alpha-Synuclein propagates  
372 from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.  
373 *Journal of Clinical Investigation*. 2011;121(2):715-25. Epub 2011/01/20. doi: 10.1172/JCI43366  
374 43366 [pii]. PubMed PMID: 21245577; PubMed Central PMCID: PMC3026723.
- 375 3. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein  
376 transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science*.  
377 2012;338(6109):949-53. Epub 2012/11/20. doi: 10.1126/science.1227157. PubMed PMID: 23161999;  
378 PubMed Central PMCID: PMC3552321.
- 379 4. Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, et al. Intrastratial injection  
380 of pre-formed mouse alpha-synuclein fibrils into rats triggers alpha-synuclein pathology and bilateral  
381 nigrostriatal degeneration. *Neurobiol Dis*. 2015;82:185-99. Epub 2015/06/21. doi:  
382 10.1016/j.nbd.2015.06.003. PubMed PMID: 26093169; PubMed Central PMCID: PMC4640952.
- 383 5. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al.  $\alpha$ -Synuclein  
384 strains cause distinct synucleinopathies after local and systemic administration. *Nature*.  
385 2015;522(7556):340-4. Epub 2015/06/11. doi: 10.1038/nature14547. PubMed PMID: 26061766.
- 386 6. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, et al. Lewy body  
387 extracts from Parkinson disease brains trigger  $\alpha$ -synuclein pathology and neurodegeneration in mice and  
388 monkeys. *Ann Neurol*. 2014;75(3):351-62. Epub 2013/11/19. doi: 10.1002/ana.24066. PubMed PMID:  
389 24243558.
- 390 7. Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal Propagation  
391 of Pathologic  $\alpha$ -Synuclein from the Gut to the Brain Models Parkinson's Disease. *Neuron*.  
392 2019;103(4):627-41.e7. Epub 2019/07/01. doi: 10.1016/j.neuron.2019.05.035. PubMed PMID: 31255487;  
393 PubMed Central PMCID: PMC6706297.
- 394 8. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, et al. Heparan sulfate proteoglycans  
395 mediate internalization and propagation of specific proteopathic seeds. *Proc Natl Acad Sci U S A*.  
396 2013;110(33):E3138-47. Epub 2013/07/31. doi: 10.1073/pnas.1301440110. PubMed PMID: 23898162;  
397 PubMed Central PMCID: PMC3746848.
- 398 9. Volpicelli-Daley LA, Gamble KL, Schultheiss CE, Riddle DM, West AB, Lee VM. Formation of alpha-  
399 synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. *Mol Biol*  
400 *Cell*. 2014;25(25):4010-23. Epub 2014/10/10. doi: 10.1091/mbc.E14-02-0741. PubMed PMID: 25298402;  
401 PubMed Central PMCID: PMC4263445.
- 402 10. Karpowicz RJ, Jr., Haney CM, Mihaila TS, Sandler RM, Petersson EJ, Lee VM. Selective imaging of  
403 internalized proteopathic alpha-synuclein seeds in primary neurons reveals mechanistic insight into  
404 transmission of synucleinopathies. *J Biol Chem*. 2017;292(32):13482-97. Epub 2017/06/15. doi:  
405 10.1074/jbc.M117.780296. PubMed PMID: 28611062; PubMed Central PMCID: PMC5555207.

- 406 11. Guédin S, Willery E, Tommassen J, Fort E, Drobecq H, Loch C, et al. Novel topological features of  
407 FhaC, the outer membrane transporter involved in the secretion of the Bordetella pertussis filamentous  
408 hemagglutinin. *J Biol Chem*. 2000;275(39):30202-10. Epub 2000/07/25. doi: 10.1074/jbc.M005515200.  
409 PubMed PMID: 10906141.
- 410 12. Cesaratto F, Burrone OR, Petris G. Tobacco Etch Virus protease: A shortcut across biotechnologies.  
411 *J Biotechnol*. 2016;231:239-49. Epub 2016/06/18. doi: 10.1016/j.jbiotec.2016.06.012. PubMed PMID:  
412 27312702.
- 413 13. Paslawski W, Lorenzen N, Otzen DE. Formation and Characterization of  $\alpha$ -Synuclein Oligomers.  
414 *Methods Mol Biol*. 2016;1345:133-50. Epub 2015/10/11. doi: 10.1007/978-1-4939-2978-8\_9. PubMed  
415 PMID: 26453210.
- 416 14. Ikenoue T, Lee YH, Kardos J, Saiki M, Yagi H, Kawata Y, et al. Cold denaturation of  $\alpha$ -synuclein  
417 amyloid fibrils. *Angew Chem Int Ed Engl*. 2014;53(30):7799-804. Epub 2014/06/13. doi:  
418 10.1002/anie.201403815. PubMed PMID: 24920162.
- 419 15. Scott DB, Blanpied TA, Swanson GT, Zhang C, Ehlers MD. An NMDA receptor ER retention signal  
420 regulated by phosphorylation and alternative splicing. *J Neurosci*. 2001;21(9):3063-72. Epub 2001/04/20.  
421 doi: 10.1523/jneurosci.21-09-03063.2001. PubMed PMID: 11312291; PubMed Central PMCID:  
422 PMC6762585.
- 423 16. Patterson JR, Polinski NK, Duffy MF, Kemp CJ, Luk KC, Volpicelli-Daley LA, et al. Generation of  
424 Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo. *Journal of visualized experiments* :  
425 JoVE. 2019;(148). Epub 2019/06/18. doi: 10.3791/59758. PubMed PMID: 31205308.
- 426 17. Jarvela TS, Lam HA, Helwig M, Lorenzen N, Otzen DE, McLean PJ, et al. The neural chaperone  
427 proSAAS blocks alpha-synuclein fibrillation and neurotoxicity. *Proc Natl Acad Sci U S A*.  
428 2016;113(32):E4708-15. Epub 2016/07/28. doi: 10.1073/pnas.1601091113. PubMed PMID: 27457957;  
429 PubMed Central PMCID: PMC4987805.
- 430 18. Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM, et al. Best Practices  
431 for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. *J*  
432 *Parkinsons Dis*. 2018. Epub 2018/02/06. doi: 10.3233/jpd-171248. PubMed PMID: 29400668.
- 433 19. Wintgens JP, Wichert SP, Popovic L, Rossner MJ, Wehr MC. Monitoring activities of receptor  
434 tyrosine kinases using a universal adapter in genetically encoded split TEV assays. *Cell Mol Life Sci*.  
435 2019;76(6):1185-99. Epub 2019/01/10. doi: 10.1007/s00018-018-03003-2. PubMed PMID: 30623207;  
436 PubMed Central PMCID: PMC6675780.

437

**Figure 1**



**Figure 2**





Figure 3



# Figure 4






Figure 5





**Figure 6A**




Figure 6B

